Repurposed drugs as histone deacetylase 8 inhibitors: Implications in cancer and neuropathological conditions
Histone deacetylase 8 (HDAC8) is a member of class I histone deacetylases (HDACs) that catalyzes the deacetylation of both histone and non-histone proteins. Dysregulation and overexpression of HDAC8 are implicated in the development of various complex diseases, including cancer and neurodegenerative...
Автори: | Mohammed Alrouji, Kumar Venkatesan, Mohammed S. Alshammari, Fahad A. Alhumaydhi, Sheeba Shafi, Sharaf E. Sharaf, Moyad Shahwan, Anas Shamsi |
---|---|
Формат: | Стаття |
Мова: | English |
Опубліковано: |
Frontiers Media S.A.
2024-11-01
|
Серія: | Frontiers in Pharmacology |
Предмети: | |
Онлайн доступ: | https://www.frontiersin.org/articles/10.3389/fphar.2024.1488585/full |
Схожі ресурси
-
ROS1 kinase inhibition reimagined: identifying repurposed drug via virtual screening and molecular dynamics simulations for cancer therapeutics
за авторством: Mohammed Alrouji, та інші
Опубліковано: (2024-07-01) -
Virtual screening and molecular dynamics simulations identify repurposed drugs as potent inhibitors of Histone deacetylase 1: Implication in cancer therapeutics.
за авторством: Mohammed Alrouji, та інші
Опубліковано: (2025-01-01) -
Identification of Potential Inhibitors of Histone Deacetylase 6 Through Virtual Screening and Molecular Dynamics Simulation Approach: Implications in Neurodegenerative Diseases
за авторством: Anas Shamsi, та інші
Опубліковано: (2024-11-01) -
Unveiling Cathepsin B inhibition with repurposed drugs for anticancer and anti-Alzheimer's drug discovery.
за авторством: Mohammed Alrouji, та інші
Опубліковано: (2024-01-01) -
Identifying Phosphodiesterase‐5 Inhibitors with Drug Repurposing Approach: Implications in Vasodysfunctional Disorders
за авторством: Mohd Shahnawaz Khan, та інші
Опубліковано: (2024-05-01)